

For the ISOQoL user's guide see <http://www.isoqol.org/UserFiles/file/UsersGuide.pdf>

as compliance to treatment) should be based on the needs of children, young people, and their families, be age appropriate, and easy for patients to use. They should also be clinically meaningful, actionable, and logistically practical from the clinical team's perspective. The International Society for Quality of Life Research (ISOQoL) developed a user's guide for implementing patient-reported outcome assessment in routine clinical practice, describing methodological and practical considerations. Successful implementation of such systems in routine clinical practice would require the engagement of everyone involved, including the patients and their families, treating clinical teams, hospital management, and funders, and would also require formal evaluation to assess the effectiveness of the system. Designing and co-producing standardised systems for symptom self-reporting in partnership with key stakeholders could improve the quality and safety of care, outcomes, and quality of life of children with cancer.

**Geetinder Kaur, Derek Kyte, Bryce B Reeve, Ethan Basch, Melanie Calvert*

Centre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK (GK, DK, MC); National Institute for Health Research Birmingham Biomedical Research Centre and National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK (DK, MC); Centre for Health Measurement, Department of Population Health Sciences and Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA (BBR); and UNC Lineberger Comprehensive Cancer Centre, School of Medicine, University of North Carolina, Chapel Hill, NC, USA (EB)
g.kaur.2@bham.ac.uk

DK reports grants from Innovate UK, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC) at the University Hospitals Birmingham NHS Foundation Trust, the University of Birmingham, Macmillan Cancer Support, and personal fees from Merck outside the submitted work. BBR is supported by a grant from the US National Cancer Institute to develop a system for children to self-report symptoms they experience while receiving cancer treatment. EB receives research funding from the US National Cancer Institute and Patient-Centered Outcomes Research Institute, is an Associate Editor for *JAMA*, and is a scientific advisor for Noona, Sivan, and the Centers for Medicare and Medicaid Services. MC reports personal fees from Astellas and Takeda, and grants from Innovate UK, NIHR, NIHR SRMRC at the University Hospitals Birmingham NHS Foundation Trust, the University of Birmingham, and Macmillan Cancer Support outside the submitted work. GK declares no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

- 1 Cancer Research UK. Children's cancer incidence statistics <http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers/incidence#heading-Two> (accessed Oct 10, 2018).
- 2 Ullrich CK, Billett AL, Berde CB. Symptom management in children with cancer. In: Orkin SH, Nathan DG, Ginsburg D, et al, eds. *Nathan and Oski's hematology of infancy and childhood*. Philadelphia: Saunders, 2009: 2349–96.
- 3 Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. *J Clin Oncol* 2016; **34**: 557–65.
- 4 Glaser AW, Davies K, Walker D, Brazier D. Influence of proxy respondents and mode of administration on health status assessment following central nervous system tumours in childhood. *Qual Life Res* 1997; **6**: 43–53.
- 5 US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. <https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf> (accessed Oct 10, 2018).
- 6 Pinheiro LC, McFatrach M, Lucas N, et al. Child and adolescent self-report symptom measurement in pediatric oncology research: a systematic literature review. *Qual Life Res* 2018; **27**: 291–319.
- 7 Leahy AB, Feudtner C, Basch E. Symptom monitoring in pediatric oncology using patient reported outcomes: why, how and where next. *Patient* 2018; **1**: 147–53.
- 8 Engelen V, Detmar S, Koopman H, et al. Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: is it effective? *Pediatr Blood Cancer* 2011; **58**: 766–74.
- 9 Schepers SA, Haverman L, Zadeh S, Grootenhuis MA, Wiener L. Healthcare professionals' preferences and perceived barriers for routine assessment of patient-reported outcomes in pediatric oncology practice: moving toward international processes of change. *Pediatr Blood Cancer* 2016; **63**: 2181–88.
- 10 Basch E. Patient reported outcomes-harnessing patients' voices to improve clinical care. *N Engl J Med* 2017; **376**: 105–08.



Increasing access to next-generation sequencing in oncology for Brazil

A new generation of sequencing technologies has provided unprecedented opportunities for personalised medical care. In oncology, next-generation sequencing can be used to predict disease risk, determine primary tumour molecular alterations, and define resistance mechanisms to therapy. To fully achieve the benefits of next-generation sequencing in oncology, obstacles

within the health-care system in which next-generation sequencing is implemented need to be overcome.

Brazil is the largest country in Latin America, with almost 210 million inhabitants, and it is estimated that cancer will become the leading cause of death in Brazil in 2028. Approximately 630 000 new cases are expected in 2018.¹ Although all Brazilians are entitled

to public health care through its national health system, Sistema Único de Saúde, which is supported by taxes and social security payments, approximately 25% of the population also purchase private health insurance.² All patients with private health insurance have the right to undergo all medically necessary procedures included in a list published by the Brazilian National Health Agency. This list is reviewed every 2 years by an expert committee comprised of delegates from several stakeholders, such as medical associations, government, pharmaceutical industries, health insurance, and patient advocacy entities. The committee do a technical analysis to consider criteria such as clinical effectiveness, budget impact, and availability of infrastructure to perform the procedure throughout the country.

Because of complex regulatory hurdles, cost, and the need for quality control guidelines, specialised personnel, and a robust bioinformatics infrastructure, the adoption of next-generation sequencing technologies requires the use of a specialised methodology, as well as a highly trained team, to collect and accurately interpret quality data. As a result, great challenges arise, both at the technical level (as a result of data management and standardisation of quality control), as well as with data interpretation and its application in the clinical setting. Despite these challenges, Brazil could emerge as a model for achieving the opportunities offered by next-generation sequencing in oncology, for Latin America.


To address the challenges associated with the implementation of next-generation sequencing in oncology for Brazil, the Americas Health Foundation did a literature review to identify scientists and clinicians, from Brazil, who have published in the field of oncology and next-generation sequencing. PubMed and Embase were used to identify experts with an academic or hospital affiliation, and who had published in the field of oncology and next-generation sequencing since 2010. As a result of this effort, the Americas Health Foundation identified and convened a seven-member panel of clinical and scientific experts from Brazil that represented the disciplines of oncology, pathology, genetics, and applied genomics. Great attention was paid to ensure recruitment of a diverse group of experts, representing various disciplines related to oncology and next-generation sequencing.

One of the first obstacles of introducing next-generation sequencing into the clinical setting is the

uncertainty regarding the interpretation of results and their application in clinical practice. Although next-generation sequencing technologies are a crucial tool in the identification of clinically actionable genetic variants, the breadth and complexity of the information acquired raises new challenges for properly analysing and interpreting the information that can then inform therapeutic guidelines. Moreover, even when relevant genetic variants are identified, there are many factors affecting patient response, such as intrinsic drug metabolism, genetic background, and tumour heterogeneity.³ Several questions remain unanswered regarding the degree to which the introduction of genome sequencing technology can actually improve patient outcomes, how to identify individuals who might benefit most from these technologies, and how to assess what negative consequences, if any, could result from routine use of this technology. Such questions pose a major challenge for governments and public health officials tasked with planning the allocation of resources for future care delivery.

A second issue involves affordability and accessibility. In countries where prices of new medicines are defined at launch for the remaining patent life, a price that will be independent of the benefit of the drug for different disease indications, there is a disincentive for the drug manufacturer to develop a test for a more well defined target population because this might affect sales. Recent technologies have improved the speed and read length of next-generation sequencing, as well as data analysis, with a decrease in price.⁴ Despite this, the cost of doing sequencing tests can still be four to five times higher than in high-income countries because of taxes and the high cost of analysis, shipment, and infrastructure.⁵

A third hurdle relates to privacy and confidentiality. Incidental findings are defined as those concerning individual patients who have potential health or reproductive relevance and are discovered in the course of testing, but are beyond the scope of the study.⁶ The ethical implications of informing patients or their relatives about potential risks or genes associated with future disease development must still be defined.⁷ The American College of Medical Genetics recently published its recommendations on this topic,⁸ and although non-binding, such recommendations are an educational source for medical practitioners; the



Philippe Plailly/Science Photo Library




Figure: Actions to increase implementation and expansion of next-generation sequencing in Brazil

development of a similar document in Brazil could encourage discussion and debate regarding practical and ethical issues.

A fourth challenge involves determining which drug is likely to work best on the basis of the molecular profile of a patient’s tumour. Although such a drug might be available on the local market, there is a considerable risk that it will not be registered for a particular disease indication, potentially encouraging off-label prescription and thus subject to reimbursement limitations.⁹

The panel identified several actions that should be implemented by the Brazilian governmental and scientific communities and non-governmental organisations to address the challenges present in the development and use of next-generation sequencing in oncology for Brazil (figure). These actions include that the government should lead initiatives to bring together stakeholders, including private and public payers, academic institutions, and industry, medical, and patient associations to do comparative cost-effectiveness analyses to better inform resource allocation for cancer care. Evaluating targeted therapies can be a challenge when the mutation in question is rare and is found in several different diseases. The traditional drug approval pathway, involving phase 1–3 trials, relies on large comparative clinical studies and might no longer be the best approach. When considering treatment approaches, genetic classification of a tumour might not follow the traditional limits

of histopathology. Furthermore, when tumour development depends on a specific pathway and the targeted therapy reliably inhibits this target, equipoise can be compromised by the possibility of some patients not receiving this specific treatment; thus a traditional randomised trial would not be ethically justifiable. Effectively treating all genetic abnormalities potentially analysed in each patient requires new trial designs and statistical methods, which could drive a shift towards smaller, but more precise, study designs, such as basket, umbrella, and adaptive trials.¹⁰ The government should sponsor the creation of a national database of genetic mutations and targeted therapy agents guided by next-generation sequencing so that patients receiving such therapy can be tracked, with information made available to physicians, payers, drug manufacturers, and regulatory agencies. Collaborative databases should encourage private and public institutions to share real-world data that can be stored and analysed. Such an initiative could facilitate the characterisation of rare mutations and link genomic findings with targeted therapy results. Population-based genomic data should also be included to account for the ethnic diversity of the Brazilian population, which will enable the use of more comprehensive next-generation sequencing panels in the near future. Medical associations and patient organisations should develop education and awareness activities to better inform patients and health-care professionals about the uses, applications, and limitations of next-generation sequencing. Academic institutions and medical associations should collaborate to develop continuing medical education for oncology-related health-care professionals on the use of next-generation sequencing. Additionally, similar efforts should be done by related medical and technical professionals. Existing national accreditation and quality control programmes should be expanded to include molecular oncology tests to guarantee quality in all steps of the molecular process, from sample preparation to result interpretation and reporting. Medical associations should bring together different stakeholders that are related to next-generation sequencing to establish national guidelines for the detection, testing, diagnosis, counselling, and surveillance of next-generation sequencing technologies. Stakeholders should consider whether the centralisation of molecular pathology services could facilitate the viability of next-generation

sequencing in a universal health-care setting. Although drawbacks to this approach include sample transport and ensuring standardisation of pre-analytical factors, next-generation sequencing platforms require substantial capital expense, specialised personnel, and a robust bioinformatics infrastructure, which could make a centralised approach faster, more accurate, more scalable, and possibly more affordable. We must also ensure that patients' autonomy and privacy is protected when performing next-generation sequencing.

All stakeholders need to be aware that new and more effective drugs and treatments could be offered to patients only after scientific research and investment has been made to produce high quality data from clinical trials. Additionally, international collaboration and genomic research expertise will improve clinical knowledge and support the development of scientific capacities for next-generation sequencing technologies.

**Marcos Santos, Renata A Coudry, Carlos Gil Ferreira, Stephen Stefani, Isabela Werneck Cunha, Mariano Gustavo Zalis, Luiz H Araujo*
UNESCO Chair of Bioethics, Faculty of Health and Sciences, University of Brasilia, CEP 70919-970, Brasilia, Brazil (MS); Anatomic Pathology Department, Hospital Sírio Libanês, São Paulo, Brazil (RAC); D'Or Institute for Research and Education, Rio de Janeiro, RJ, Brazil (CGF); Mãe de Deus Cancer Center, Porto Alegre, Brazil (SS);

Pathology Department, Rede D'OR São Luiz, Sao Paulo, Brazil (IWC); Department of Research and Development, Instituto Hermes Pardini, Vespaziano, Minas Gerais, Brazil (MGZ); Brazilian National Cancer Institute, Rio de Janeiro, RJ, Brazil (LHA); and COI Institute for Education and Research, Rio de Janeiro, RJ, Brazil (LHA).
mrcsantos@unb.br

The organization and implementation of the consensus conference was carried out by the Americas Health Foundation, a 501(c)3 nonprofit organization dedicated to improving healthcare throughout the Latin American Region, and was supported by an unrestricted grant from Roche. We declare no other competing interests.

- 1 Conselho Federal de Medicina. Cancer is already the leading cause of death in 10% of Brazilian municipalities, study says. April 16, 2018. https://portal.cfm.org.br/index.php?option=com_content&view=article&id=27575:2018-04-16-17-37-16&catid=3 (accessed Dec 14, 2018).
- 2 Ferreira CG, Achatz MI, Ashton-Prolla P, Begnami MD, Marchini FK, Stefani SD. Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing. *Lancet Oncol* 2016; **17**: e363–70.
- 3 Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. *Cancer Lett* 2013; **340**: 284–95.
- 4 van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. *Trends Genet* 2014; **30**: 418–26.
- 5 Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: challenges and solutions. *Appl Trans Genom* 2016; **9**: 15–19.
- 6 Wolf SM. Return of individual research results and incidental findings: facing the challenges of translational science. *Annu Rev Genomics Hum Genet* 2013; **14**: 557–77.
- 7 Holtzman NA. ACMG recommendations on incidental findings are flawed scientifically and ethically. *Genet Med* 2013; **15**: 750–51.
- 8 Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet Med* 2016; **19**: 249.
- 9 Schilsky RL. Implementing personalized cancer care. *Nat Rev Clin Oncol* 2014; **11**: 432–38.
- 10 Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. *Nat Rev Clin Oncol* 2018; **15**: 183–92.

Intraoperative lymph-node assessment during NSCLC surgery: the need for standardisation and quality evaluation



Analyses of large contemporaneous national databases, even in the era of modern pre-treatment staging methods, show a 10–20% incidence of nodal upstaging in patients with clinical stage I non-small-cell lung cancer (NSCLC) and treated with lobectomy.¹ Therefore, lymphadenectomy is still heralded as a hallmark of surgical quality. However, this opinion is often poorly adhered to in clinical practice. Similarly, clinical research is not free from low adherence: in the randomised ACOSOG Z4032 trial,² which compared sublobar resection alone with sublobar resection and brachytherapy in patients with clinical stage I NSCLC, more than a third of the patients did not receive any kind of lymph node evaluation.² International guidelines about what constitutes an adequate nodal

dissection differ in their specific requirements, and major intercontinental variation in pathological node status (pN) category-stratified survival has been reported.³ Even if underlying racial differences in lung tumour biology contribute to this variation, there are also possible disparities related to the aggressiveness of preoperative and intraoperative nodal assessment that lead to differences in outcomes.

Thoroughness of pathological node examination in surgical cohorts can be accurately assessed as the number of lymph nodes and stations removed, because the use of sequentially more stringent nodal criteria leads to the best prognostic delineations.⁴ In patients with pN1–2 NSCLC, the lymph node ratio—the number of positive lymph nodes versus the total number of

